Prostaglandin E1 in heart disease: Review and perspective

American Journal of Therapeutics

Volumn 4, Issue 11-12, 1997, Pages 353-358

  Rabinowitz, Babeth ^a   Schollmayer, Erwin ^a   Weiss, Marija ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; PROSTAGLANDIN E1;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TREATMENT OUTCOME; HEART DISEASE; HEART SURGERY; REVIEW;

ALPROSTADIL; ARTERIAL OCCLUSIVE DISEASES; CARDIAC SURGICAL PROCEDURES; CORONARY DISEASE; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; PERIPHERAL VASCULAR DISEASES;

EID: 0030608608     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199711000-00003     Document Type: Conference Paper

References (60)

1. 1 in patients with peripheral vascular disease. Adv Prostaglandin Thromboxane Leukotpriene Res 1976;1: 429-432.
2. 1 in infants with ductus arteriosus dependent congenital heart disease. Circulation 1981;64: 899.
3. 2 on pulmonary vascular resistance in the dog. Proc Soc Exp Biol Med 1975;149:282.
4. 1 in pulmonary hypertension. Crit Care Med 1986;14:72-73.
5. 1 treatment of pulmonary hypertension. Am Rev Respir Dis 1987; 136:773-776.
6. 1 and survival in patients with adult respiratory distress syndrome. Ann Surg 1986;203:371-378.
7. 1 - long-term results of an international multicenter study according to the GCP-standard. Int J Impot Res 1994;6(Suppl 1):D108.
8. 1. Transplantation 1989;48:447-453.
9. 1 - a preliminary report. Dig Dis Sci 1991;36:791-800.
10. Packer M: Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure. Circulation 1988;77(Suppl I):I64-I73.
11. 1 infusion in patients with chronic renal disease. Lancet 1982;1:687.
12. 1 infusion in patients with acute myocardial infarction and left ventricular failure. Am Heart J 1982;130:485-489.
13. 1 in patients before and during cardiopulmonary bypass. Eur Surg Res 1980;12(Suppl 1):49.
14. 1 on fractional distribution of cardiac output and organ blood flow in man: a simultaneous and non-invasive determination using double dose thallium-201 scintigraphy. Cardiovasc Res 1984;18:657-662.
15. 1 and isoproterenol early after cardiac operations for mitral stenosis. J Thorac Cardiovasc Surg 1992;103(6):1177-1185.
16. 1 in coronary artery disease. Am J Cardiol 1988;62:698-702.
17. 1 during cardiopulmonary bypass in infants and children. Jpn J Surg 1982;12:19-25.
18. 1 in severe dilated cardiomyopathy. Clin Pharmacol Ther 1993;52:203.
19. 1 in severe left ventricular failure due to chronic coronary heart disease. Am Heart J 1981;102:703-709.
20. 1 versus pentoxifylline therapy in chronic arterial occlusive disease - a controlled randomised multicenter study. Vasa 1989;28(Suppl):44-49.
21. 1). Soc Vasc Surg Joint Ann Meeting 1995; P15:22.
22. 1 (Eds. Heidrich H, Boehme H, Rogatti W), Springer, Berlin, 1988, pp 133-143.
23. 1-Therapie im Stadium IIb. Vasa 1994;43(Suppl):90.
24. 1 on forearm blood flow. Scand J Clin Lab Invest 1969;23:347-353.
25. Kloeze J: Influence of prostaglandins on platelet adhesiveness and platelet aggregation. In: Nobel Symposium 2, Prostaglandins (Eds. Bergstrom S, Samuellson B), Almqvist and Wiksell, Stockholm 1967, pp 241-252.
26. Schroer K: Prostaglandine und Verwandte Substanzen. Thieme, Stuttgart, 1984.
27. 1: in vivo modulation of the formyl peptide chemotactic receptor on the rat neutrophil. J Immunol 1983;130:1495-1497.
28. 2. Arch Pharmacol 1990;341:308-315.
29. 2 on lipolysis, platelet aggregation, smooth muscle and the cardiovascular system. J Pharm Pharmacol 1969;21:103-108.
30. 1 on platelet function in vitro and in vivo. Br J Haematol 1970;19:559-571.
31. 1 and norepinephrine on lipid and glucose metabolism in isolated perfused rat liver overloaded with a lipid substrate. Biochim Biophys Acta 1972;280:458-465.
32. 1: anomalous effects on glucose production in rat liver. Mol Pharmacol 1975;11:335-339.
33. 1 in Atherosclerosis (Eds. Sinzinger H, Rogatti W), Springer, Berlin, 1986, pp 49-53.
34. 1 in Atherosclerosis (Eds. Sinzinger H, Rogatti W), Springer, Berlin, 1986, pp 39-48.
35. 1 suppress sterol synthesis in freshly isolated human mononuclear leukocytes. Biochim Biophys Acta 1985; 835:154-157.
36. 1 in Atherosclerosis (Eds. Sinzinger H, Rogatti W), Springer, Berlin, 1986, pp 32-38.
37. 1 infusion in unstable angina: effects on anginal frequency and cardiac function. Am Heart J 1984;108:863-868.
38. 1 plus streptokinase in acute myocardial infarction. Am J Cardiol 1986;58:1161-1166.
39. 1 to streptokinase improves thrombolysis and left ventricular function in acute myocardial infarction. J Am Coll Cardiol 1988;11(Suppl 2):104A.
40. 1 administration in unstable angina patients undergoing PTCA: preliminary results. Eur Heart J 1990;11:2062.
41. 1 infusion after angioplasty in humans inhibits abrupt occlusion and early restenosis. Adv Prostaglandin Thromboxane Leukotriene Res 1987;17:266-270.
42. 1 during angioplasty (PTCA) as preventive therapy of coronary restenosis. Am J Ther 1997;4:395-400.
43. 1 for refractory right heart failure after coronary artery bypass grafting. J Cardiothorac Anesth 1988;2:56-59.
44. 1 for prevention of hemolysis. J Jpn Assoc Thorac Surg 1990;38:625-629.
45. 1 during cardiopulmonary bypass. Eur J Anaesth 1991;8:129-134.
46. El-Gatit A, Al-Khaja N, Belboul A, Radberg G, Roberts D: Influence of alprostadil on pulmonary dysfunction after a cardiac operation. Ann Thorac Surg 1992;53:1018-1022.
47. 1 facilitates weaning from cardiopulmonary bypass. Jpn J Anaesth 1990;39:343-348.
48. 1 in patients undergoing clinical cardiopulmonary bypass. Ann Thorac Surg 1983;35:406-414.
49. 1: a new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement. J Thorac Cardiovasc Surg 1985;89:567-572.
50. 1 requirement for heart transplantation. J Heart Lung Transplant 1992;11:724-726.
51. 1. J Heart Lung Transplant 1993;12(Suppl):S191-S194.
52. 1-induced moderation of elevated pulmonary vascular resistance. Survival on waiting list and results of orthotopic heart transplantation. J Heart Lung Transplant 1993;12:173-178.
53. Murali S, Uretsky BF, Sudhakar Reddy P, Tokarczyk TR, Bertschart AR: Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: comparative effects of various pharmacologic agents. Am Heart J 1991;12:1375-1381.
54. 1 Infusion als medikamentoese Ueberbrueckungstherapie vor Herztransplantation bei therapierefraktaerer Herzinsuffizienz. A Kardiol 1994;83 (Suppl):664.
55. 1 treatment to prevent right ventricular failure after orthotopic heart transplantation. Transplant Int 1992;5(Suppl 1):S224-S227.
56. 1 infusion improves the hemodynamic state in advanced congestive heart failure and reduces elevated ANP levels. J Cardiothorac Anesth 1990;4:95.
57. 1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. Am J Ther 1997;4:365-374.
58. 1 in patients with moderate to severe chronic heart failure. Am J Ther 1997;4:381-388.
59. 1 on extravascular lung water in patients with severe heart failure. Am J Ther 1997;4:389-394.
60. 1 and buflomedil on left ventricular function in patients with severe chronic occlusive arterial disease: a prospective, randomized, double-blind trial. Am J Ther 1997;4:375-380.